Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Cirmena G, Ferrando L, Ravera F, Garuti A, Dameri M, Gallo M, Barbero V, Ferrando F, Del Mastro L, Garlaschi A, Friedman D, Fregatti P, Ballestrero A, Zoppoli G. Cirmena G, et al. JCO Precis Oncol. 2022 Feb;6:e2100198. doi: 10.1200/PO.21.00198. JCO Precis Oncol. 2022. PMID: 35201850 Free PMC article.
HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22).
Aliano S, Cirmena G, Garuti A, Fugazza G, Bruzzone R, Rocco I, Malacarne M, Ballestrero A, Sessarego M. Aliano S, et al. Among authors: cirmena g. Cancer Genet Cytogenet. 2007 Sep;177(2):115-9. doi: 10.1016/j.cancergencyto.2007.05.009. Cancer Genet Cytogenet. 2007. PMID: 17854665
Immunotherapy with dendritic cells for cancer.
Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Ballestrero A, et al. Among authors: cirmena g. Adv Drug Deliv Rev. 2008 Jan 14;60(2):173-83. doi: 10.1016/j.addr.2007.08.026. Epub 2007 Oct 5. Adv Drug Deliv Rev. 2008. PMID: 17977615 Review.
APO866 activity in hematologic malignancies: a preclinical in vitro study.
Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, Rocco I, Cirmena G, Casciaro S, Olcese F, Pierri I, Cagnetta A, Ferrando F, Ghio R, Gobbi M, Ballestrero A, Patrone F, Nencioni A. Cea M, et al. Among authors: cirmena g. Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8. doi: 10.1182/blood-2009-03-209213. Blood. 2009. PMID: 19498032 Free article. No abstract available.
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
Ballestrero A, Cirmena G, Dominietto A, Garuti A, Rocco I, Cea M, Moran E, Nencioni A, Miglino M, Raiola AM, Bacigalupo A, Patrone F. Ballestrero A, et al. Among authors: cirmena g. Int J Lab Hematol. 2010 Aug 1;32(4):387-91. doi: 10.1111/j.1751-553X.2009.01198.x. Epub 2009 Nov 30. Int J Lab Hematol. 2010. PMID: 19968720
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, Palermo C, Pica G, Pierri I, Miglino M, Ballestrero A, Gobbi M, Patrone F. Carella AM, et al. Among authors: cirmena g. Leuk Lymphoma. 2010 Feb;51(2):275-8. doi: 10.3109/10428190903503446. Leuk Lymphoma. 2010. PMID: 20038234
Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A, Nencioni A. Zoppoli G, et al. Among authors: cirmena g. Curr Cancer Drug Targets. 2010 Mar;10(2):168-75. doi: 10.2174/156800910791054211. Curr Cancer Drug Targets. 2010. PMID: 20088787
38 results